Screener
Integra LifeSciences IART Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Integra LifeSciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000917520-26-000041
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payments for contingent considerations | — | (2,600) |
| Proceeds from exercised stock options and employee stock purchase plan | 760 | 957 |
| Cash taxes paid in net equity settlement | (1,375) | (2,136) |
| Net cash provided by financing activities | 8,297 | 35,377 |
| Effect of exchange rate changes on cash and cash equivalents | (1,491) | 4,529 |
| Net increase (decrease) in cash and cash equivalents | 1,761 | (7,271) |
| Cash and cash equivalents at beginning of period | 235,048 | 246,375 |
| Cash and cash equivalents at end of period | $236,809 | $239,104 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's financing cash flow?
- Integra LifeSciences (IART) reported financing cash flow of $8.3M in Q1 2026.
- How has Integra LifeSciences's financing cash flow changed year-over-year?
- Integra LifeSciences's financing cash flow decreased by 76.5% year-over-year, from $35.38M to $8.3M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Integra LifeSciences's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude